What counts as “post-patent” revenue for Lipitor, and why comparisons are hard
“Post-patent revenue” for Lipitor generally refers to the period after Pfizer’s marketing exclusivity ended in major markets, when branded sales typically fall as generic atorvastatin enters and pricing drops. But public figures differ on what they include (for example, whether they track worldwide net sales, specific countries, or the immediate “switch” period versus later years), so direct apples-to-apples comparisons to generic manufacturers’ revenue are rarely possible using only high-level information.
Because your question asks specifically how Lipitor’s post-patent revenue compares to atorvastatin generics, the key missing piece is the underlying dataset: Lipitor revenue after loss of exclusivity versus aggregate generic atorvastatin revenue in the same timeframe and geography.
How the generic switch usually changes revenue patterns (branded vs. generics)
In most blockbuster “patent cliff” cases, branded revenue (Lipitor) tends to decline rapidly after the first generic entrants capture share through price competition. Generic competitors’ total sales may rise after entry, but each company’s revenue is typically smaller than the former brand’s worldwide sales, and pricing per pill is lower. This creates two common effects:
- Branded “post-patent” revenue usually reflects a steep decline in net sales as generics substitute.
- Generic “post-entry” revenue is spread across multiple manufacturers, with total market revenue often falling compared with the brand monopoly period due to lower prices.
What you’d need to quantify “compare to atorvastatin generics”
To answer your question numerically, you’d typically line up:
1. The exact endpoint of Lipitor exclusivity (by country/region and year).
2. Lipitor’s net sales for a consistent window after that date (for example, 1–3 years after exclusivity loss, or annual figures for 5+ years).
3. The total market revenue for generic atorvastatin (not just one generic company) over the same window, ideally from the same reporting source.
4. Whether you compare revenue by “wholesale market value,” “manufacturer revenue,” or “retail spend,” since each can tell a different story.
Common ways analysts present the comparison
Even without country-by-country details, analysts often compare in one of two ways:
- Share-based: Lipitor’s branded volume and remaining revenue share versus the generic segment’s volume and revenue share after entry.
- Price-based: branded average selling price per unit versus generic average price per unit, then apply it to volume to estimate revenue impact.
If you share the numbers or the source you’re using, the comparison can be made precisely
If you paste the Lipitor post-patent revenue figure(s) you’re looking at and the corresponding generic atorvastatin revenue figures (or a link/table with them), I can compute:
- Percent decline for Lipitor after exclusivity
- Generic segment revenue increase (if you have pre/post data)
- Revenue share split and the implied average price impact
Sources
None were provided in the prompt, so I can’t cite any specific revenue figures for Lipitor or generic atorvastatin.